News

Virginia Catalyst announces Grant Round 14 awarded projects

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in the Commonwealth of Virginia, pending execution of the grant agreements. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 14 of Virginia Catalyst’s ongoing mission to stimulate economic development by promoting collaborative projects that address large, unmet needs for improving human health, and that can create high-paying jobs in the Commonwealth.

“We are excited to continue our mission of supporting collaborations and fostering economic growth in Virginia’s life sciences, enabling the Commonwealth to compete on a national and global scale,” said Mike Grisham, CEO, Virginia Catalyst. “The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the Commonwealth.”

Through this 14th round of funding, Virginia Catalyst has awarded 57 grants totaling $27 million, resulting in over $44 million in matching funds and an additional $665 million in follow-on funding to date.

The awards, which range from $200,000 to $800,000, help fund collaborative efforts between industry and Virginia research universities with the goal of:

  • Funding innovative, collaborative, translational research projects that elevate the level of sponsored research at Virginia’s universities and have the potential to significantly improve human health and create high value jobs in the Commonwealth
  • Accelerating commercialization of Virginia research university inventions and discoveries and to achieve competitive critical mass through robust collaborations of Virginia research universities and industry

Grant Round 14 project awardees:

Project: RNA Based Precision Medicine for Lupus Disease Management

  • Company: AMPEL BioSolutions, LLC (Charlottesville, VA)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $800,000

Project: Commercialization of Intelligent Data-Driven Pulmonary Embolism Endovascular Therapy: The VersusTM Solution

  • Company: Liquet Medical (Glen Allen, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $368,797

Project: A Novel Platform for Treatment of High Dose Ionizing Radiation

  • Company: The Tiny Cargo Company (Roanoke, VA)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $350,000

Project: A Hybrid Alpha-pseudovirus, Multi-viral Nasal Vaccine Platform

  • Company: Virongy Biosciences (Manassas, VA)
  • University collaborators: George Mason University and Virginia Tech
  • Funding amount: $500,000

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital